Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 115,935

Document Document Title
WO/2024/003560A1
The present invention provides a novel composition comprising Ashwagandha root (Witbania somnifera), Turmeric root (Curcuma longa), Lemon Balm Leaf (Melissa officinalis), Rhodiola Rosea root and Bilberry fruit (Vaccinium myrtillus). The ...  
WO/2024/006977A1
This invention reports rational design, synthesis, and characterization of a series of a delta opioid receptor (DOR)-selective bitopic ligands targeting a conserved sodium site in DOR. The design is based on modifications in a selective ...  
WO/2024/004231A1
The present invention addresses the problem of providing a novel γ-secretase inhibitor that has as an active ingredient a substance for which a γ-secretase inhibitory activity is heretofore unknown. The present invention provides a γ-...  
WO/2024/003385A1
The invention relates to a nutritional composition comprising a combination of (i) omega-3 fatty acid DHA with (ii) vitamin B2 and (iii) vitamin D3 for use in the treatment of neurodegenerative diseases and/or neurotrauma. The invention ...  
WO/2024/005124A1
The present invention relates to: a method for producing a non-human primate model of cerebral infarction, said method including administering an endothelin to the cerebral basal ganglia and thalamic area of a non-human primate and thus ...  
WO/2024/005197A1
Provided are: a solid dispersion comprising at least one compound selected from the group consisting of a hetero ring derivative represented by general formula [1], a tautomer of the hetero ring derivative, and a pharmaceutically accepta...  
WO/2024/005578A1
The present invention relates to novel indenone derivatives, isomers thereof or pharmaceutically acceptable salts thereof, and uses thereof. The indenone derivatives according to the present invention may be advantageously used for (i) t...  
WO/2024/003805A1
Compositions and methods for inducing a double-stranded break (DSB) within the TTR gene, and/or modifying the TTR gene are provided. Compositions and methods for treating amyloidosis associated with TTR (ATTR), and/or reducing TTR serum ...  
WO/2024/003610A1
The present disclosure provides a method of treating or ameliorating a disease or disorder comprising administering to a subject a crystalline form of a composition comprising crystalline forms A, B, and C of psilocin and psilocybin. The...  
WO/2024/006773A1
The present invention provides methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators, and compositions having low impurity levels.  
WO/2023/247312A1
Transthyretin amyloidosis is characterized by progressive deposition of the plasma protein transthyretin in the myocardium, peripheral nerves and/or other tissues, which can ultimately lead to congestive heart failure, polyneuropathy and...  
WO/2023/248222A1
A method of treating a disease or disorder for which an increase in immune cells in the brain is therapeutic in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent whic...  
WO/2023/247604A1
The present disclosure relates to methods for enhancing mental performance and compositions, typically mental performance enhancing compositions, suitable for use in such methods. The present disclosure also relates to consumer products ...  
WO/2023/247789A1
The present invention relates to a complex comprising i) a catalytically inactive site-specific nuclease linked to ii) an array of between two and ten, preferably three to seven effector domains each having a specific chromatin modifying...  
WO/2023/249924A1
Methods of treating sleep apnea and snoring comprising administering a combination of a cannabinoid and a carbonic anhydrase inhibitor (CAI), and optionally a muscarinic receptor antagonist (MRA), are described herein. Pharmaceutical com...  
WO/2023/250249A1
As described herein, inhibitors of High mobility group box protein 1 (HMGB1) can significantly reduce HMGB1 nucleo-cytoplasmic translocation, gliosis, neurodegeneration, Tau pathologies, and myelin deficits, especially in subjects having...  
WO/2022/256283A9
The present invention relates to methods and compositions for restoring function of a pathogenic protein, the method comprising contacting a polynucleotide encoding the pathogenic protein with a guide oligonucleotide capable of effecting...  
WO/2023/249461A1
Provided are: sustained-release microspheres comprising donepezil or a pharmaceutically acceptable salt thereof, pamoic acid, and a biocompatible polymer; a pharmaceutical composition for preventing, improving, or treating Alzheimer's di...  
WO/2023/250156A1
4-Alkoxypyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of 4-alkoxypyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof...  
WO/2023/249007A1
The present invention provides a calpain inhibitor that has excellent calpain inhibitive capacity. The present invention provides a compound represented by general formula (I), or a salt thereof. (In formula (I), R1 represents a hydrogen...  
WO/2023/250060A1
Alkoxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Dis...  
WO/2023/249989A1
Described herein are solid forms of 3-(((2S,3S)-8-methoxy-2-(6-methoxypyridin-3-yl)-3-methyl-2,3 -dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H-imidazo[4,5-b]py ridine-2-d, process of preparing the forms, pharmaceutical compositions, and me...  
WO/2023/249789A1
The present disclosure relates to methods for treating subjects having a substance use disorder (SUD) with 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 negative allosteric modulators. Specifically, in some embodiments, this disclosure r...  
WO/2023/250083A1
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecule compounds having a 6,6-heterocyclic structure (e.g., compounds having a naphthyridine, pyrido-pyridazine, pyrido...  
WO/2023/247670A1
The present invention provides compounds of formula (I) CB (I) or pharmaceutically acceptable salts thereof, wherein R3 to R5, R4a, B and C are as described herein, compositions including the compounds, processes of manufacturing the com...  
WO/2023/247946A1
The invention relates to an oral dosage form comprising phenelzine and a film coating, characterised in that said film coating is an aqueous based film coating. The invention also relates to said oral dosage form for use in the treatment...  
WO/2023/250002A1
The present disclosure is concerned with benzothiazone compounds that are capable of inhibiting Tau-SH3 signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders...  
WO/2023/248161A1
Solid state forms of Dibuprenorphine-ethyl-ether and Dibuprenorphine-ethyl-ether 2HCl are provided, as well as processes for the preparation thereof, and pharmaceutical compositions thereof.  
WO/2023/248374A1
It is considered that diabetes-associated dementia is mainly caused by insulin resistance and relative insulin deficiency in the brain. Meanwhile, delivery of drugs to the brain is inhibited by the blood-brain barrier, and therefore, the...  
WO/2023/247665A1
The present disclosure relates to stable pharmaceutical compositions of amorphous psilocybin and deuterated psilocybin, and to the use of such pharmaceutical compositions in the treatment of diseases associated with a serotonin 5-HT2 rec...  
WO/2023/248206A1
The present invention provides a composition for preventing or treating a neurodegenerative disease containing a phosphodiesterase 5 inhibitor (PDE5 inhibitors) and an acetylcholinesterase inhibitor (AChEI) and a method using thereof, we...  
WO/2023/249107A1
The purpose of the present invention is to provide a therapeutic agent or prophylactic agent for peripheral nerve disorders, the agent having a ferroptosis inhibitory action. The present invention provides a therapeutic agent or prophy...  
WO/2023/249965A1
The present application relates to compounds of Formula (I), Formula (II), and Formula (III) and to pharmaceutically acceptable salts and solvates of any of the foregoing, as well as pharmaceutical compositions and methods of using same ...  
WO/2023/246642A1
Disclosed are a composition for treating spinal cord injury, a preparation method therefor and a use thereof. The composition comprises induced neural stem cells, fibrin and thrombin, and is particularly applicable for fully injured and ...  
WO/2023/246644A1
The present invention provides a spinal progenitor cell for treating amyotrophic lateral sclerosis (ALS). The spinal progenitor cell is represented as at least any two of PAX6+, SOX1+, Nkx6.1+, SOX2+, DBX2+, OLIG2+, PAX3+, or Nkx2.2+, an...  
WO/2023/246944A1
The present invention relates to a substituted 4-aminoisoindoline compound, a preparation method therefor, a pharmaceutical composition thereof, and use thereof. The compound has a structure represented by formula (I). Specifically, the ...  
WO/2023/201350A9
A composition and method for treatment of opioid use disorder (OUD) is provided by expressing a novel mu receptor mutant, LAMuOR (Low Affinity Mu Opioid Receptor), with reduced binding affinity for opioids such that it is activated only ...  
WO/2023/246872A1
Provided are a heterocyclic compound used as a TAAR1 agonist, a preparation method of the compound, a pharmaceutical composition containing the compound, and a use of the compound as a TAAR1 agonist in preventing and/or treating various ...  
WO/2023/250141A2
Disclosed in certain embodiments are methods of treating neurological ventilatory insufficiency comprising administering to patient in need thereof, an effective amount of a compound selected from Formula (I) as disclosed herein.  
WO/2023/250334A1
In various aspects and embodiments provided are compositions and methods for treating subjects in need thereof. In some embodiments, the compositions and methods involve purified or isolated isomers of nadolol. In one aspect, the disclos...  
WO/2023/246865A1
Provided is a pharmaceutical composition including buprenorphine, a derivative thereof, or a pharmaceutically acceptable salt thereof, a stabilizer, a biocompatible solvent, and at least one compound represented by Formula (IIA), (IIB) o...  
WO/2023/245670A1
The invention described herein provides methods and compositions for treating certain diseases, using a composition for regulating a primate PTBP gene expression comprising a Cas effector protein and a guide RNA (gRNA) to target a target...  
WO/2023/250059A1
Cycloalkylmethoxy- and cycloalkyloxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourett...  
WO/2023/247774A1
The present disclosure relates to a novel treatment regimen for the treatment of autoimmune diseases and other inflammatory diseases with BTK (Bruton's tyrosine kinase) inhibitors. In particular, the present disclosure relates to a treat...  
WO/2023/248154A1
The present invention relates to an improved process for the preparation of viloxazine or its pharmaceutically acceptable salts such as the hydrochloride salt. Further, the present invention relates to a novel compound designated herein ...  
WO/2023/250332A1
In various aspects and embodiments provided are compositions and methods for treating subjects in need thereof. In some embodiments, the compositions and methods involve purified or isolated isomers of nadolol. In one aspect, the disclos...  
WO/2023/248689A1
Provided is a novel climacteric disorder ameliorating agent. A climacteric disorder ameliorating agent according to the present invention includes a powder or an extract of Paecilomyces tenuipes. Such climacteric disorder ameliorating ...  
WO/2023/250388A1
The present disclosure provides anti-tau antibodies and adeno-associated virus (AAV) particles with an AAV genome encoding anti-tau antibodies. Also provided are methods of using anti-tau antibodies and AAV particles for treatment and di...  
WO/2023/250440A1
Extracellular vesicles comprising a bi-layer lipid membrane comprising an inner layer and an outer layer and a first recombinant protein comprising a first transmembrane moiety embedded between the inner layer and the outer layer of the ...  
WO/2023/250185A1
The disclosure relates to Compound 1 and crystalline solid forms and solid dosage forms thereof. The disclosure also provides methods of preparing and methods of using said crystalline solid forms of Compound 1 and solid dosage forms the...  

Matches 401 - 450 out of 115,935